Bayer and Onyx Initiate Enrollment for Phase III Liver Cancer Trial
Posted on: Friday, 22 August 2008, 06:00 CDT
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have initiated enrolling patients in the Storm sorafenib as adjuvant treatment in the prevention of recurrence of hepatocellular carcinoma trial.
The randomized, double-blind, placebo-controlled Phase III study is evaluating Nexavar (sorafenib) tablets as adjuvant treatment, which is treatment following surgery or local radiation, for patients with hepatocellular carcinoma (HCC), or primary liver cancer.
In addition, the FDA has completed a special protocol assessment (SPA) for the Storm trial. An SPA is a written agreement on the design and size of a clinical trial intended to form the basis for a new drug application.
The international multicenter study is expected to enroll approximately 1,100 patients and will include patients who have received surgical resection or local ablation. The study will look at whether providing oral Nexavar in the adjuvant setting delays the time to recurrence and increases overall survival.
The primary endpoint of the study is recurrence free survival. Secondary endpoints include overall survival, time to recurrence, patient-reported outcomes, plasma biomarkers, safety and tolerability.
The study is enrolling patients with all HCC histologies. Patients will be randomized to receive 400mg of Nexavar twice daily or matching placebo for up to four years. The study will be conducted at more than 200 sites in North America, South America, Europe and the Asia-Pacific region, including Japan.
Source: Datamonitor
Related Articles
- Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
- Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
- ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
- Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
- Dosing Initiated in TransMolecular's Phase 1/2 Clinical Trial for Intravenous Administration of (131)Iodine-TM601 in Patients With Recurrent Malignant Glioma
- Oncophage(R) Cancer Vaccine Significantly Prolongs Recurrence-Free Survival By 45 Percent in Patients With Intermediate-Risk Kidney Cancer
- Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating Glufosfamide in Patients With Recurrent, Sensitive Small Cell Lung Cancer
- UroToday.Com Reports of a Model That Predicts Survival Time in Patients With Recurrent Renal Cell Carcinoma
- ARIMIDEX(R) (Anastrozole) Featured in Studies Evaluating Impact of Switching on Survival in Adjuvant Treatment of Early Breast Cancer
- ARIAD Initiates Phase 2 Clinical Trial of AP23573 in Patients With Recurrent or Persistent Endometrial Cancer; Over 40,000 New Cases of Endometrial Cancer Expected in 2005
 |
 |
User Comments (0)
RSS Feeds